Capricor Therapeutics, Inc. (CAPR)

Capricor Therapeutics' stock price experienced a substantial decline of 71.11% between October 28, 2024, and October 24, 2025. In July 2025, the FDA issued a Complete Response Letter for Deramiocel, leading to a 39% drop in shares. In August 2025, the first subjects were dosed in a Phase 1 clinical trial for its novel exosome-based vaccine. In September 2025, positive regulatory updates regarding Deramiocel led to a 9.1% stock surge after resolving all 483 Pre-License Inspection observations and scheduling a Type A meeting with the FDA. In October 2025, Weiss Ratings reiterated a "Sell (D-)" rating, while other analysts maintained "Buy" or "Overweight" ratings, and the company reported Q2 2025 financial results, missing consensus EPS estimates.

Capricor Therapeutics' products and services are not subject to typical demand seasonality because they are focused on developing therapies for rare diseases like Duchenne muscular dystrophy. Demand is driven by disease prevalence and clinical need rather than seasonal fluctuations.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company in the Medical sector, focusing on Pharmaceutical and Medical Products. They advance cell and exosome-based therapies, with major product candidates including Deramiocel (CAP-1002) for Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD), the StealthX™ Exosome Platform for infectious diseases like SARS-CoV-2, and CAP-2003 for DMD in preclinical trials. Deramiocel aims to preserve cardiac and skeletal muscle function in muscular dystrophies. The StealthX™ platform is being developed for infectious diseases, including an exosome protein-based vaccine for SARS-CoV-2, which has entered Phase 1 clinical trials. CAP-2003 is an allogeneic cardiosphere-derived cell exosome product in preclinical trials for DMD.

Capricor Therapeutics, Inc. is headquartered in San Diego, California, United States.

Capricor Therapeutics' brand reputation has been influenced by clinical developments and regulatory setbacks. The company has received "Moderate Buy" consensus ratings from analysts, but Weiss Ratings maintains a "Sell (D-)" rating. Blogger sentiment and crowd wisdom have generally been bullish or positive. The FDA's refusal to approve Deramiocel in July 2025 led to a stock price drop, but subsequent positive regulatory updates in September 2025 helped mitigate concerns. Additionally, a class-action lawsuit against Capricor Therapeutics, Inc. could negatively impact its brand reputation.

Capricor Therapeutics (NASDAQ: CAPR) has a diverse ownership structure. Institutional shareholders hold approximately 30.06% of the stock, while Capricor Therapeutics insiders own about 85.19%. Individual investors hold a significant 47% stake in the company. Major institutional owners include BlackRock, Inc., Vanguard Group Inc., State Street Corp., Geode Capital Management, LLC, and Susquehanna International Group, Llp. Nippon Shinyaku Co., Ltd. is the largest individual shareholder, owning 7.09 million shares, representing 15.51% of the company.